RUNX1 and acute lymphoblastic leukemia: Even more, when the CD19-ETV6-RUNX1 model [18] was crossed with a vav-Bcl2 transgenic model resulted in shortened latency to follicular lymphoma [19], but the double transgenic mice did not develop pB-ALL (Table 1).